Medical Management of Growth Hormone-Secreting Pituitary Adenomas
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in Pituitary
- Vol. 5 (2) , 67-76
- https://doi.org/10.1023/a:1022356313153
Abstract
The primary treatment of acromegaly remains transsphenoidal adenomectomy, yet the tissue overgrowth of acromegaly often progresses following surgery, and responds to radiotherapy only after...Keywords
This publication has 97 references indexed in Scilit:
- Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonistThe Lancet, 2001
- Hormonal and Metabolic Effects of Radiotherapy in Acromegaly: Long-Term Results in 128 Patients Followed in a Single CenterJournal of Clinical Endocrinology & Metabolism, 2000
- Outcome of Radiotherapy for Acromegaly Using Normalization of Insulin-Like Growth Factor I to Define Cure*Journal of Clinical Endocrinology & Metabolism, 2000
- Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?Acta Endocrinologica, 1998
- Evaluation of Disease Status with Sensitive Measures of Growth Hormone Secretion in 60 Postoperative Patients with Acromegaly 1Journal of Clinical Endocrinology & Metabolism, 1998
- Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly1Journal of Clinical Endocrinology & Metabolism, 1998
- Determinants of clinical outcome and survival in acromegalyClinical Endocrinology, 1994
- Rational Design of Potent Antagonists to the Human Growth Hormone ReceptorScience, 1992
- Plasma Insulin-Like Growth Factor-I/Somatomedin-C in Acromegaly: Correlation With the Degree of Growth Hormone Hypersecretion*Journal of Clinical Endocrinology & Metabolism, 1988
- Treatment of Acromegaly with the Long-Acting Somatostatin Analog SMS 201-995*Journal of Clinical Endocrinology & Metabolism, 1988